David Arlen SCHAER,Richard A. WALGREN,Sau-Chi Betty YAN
申请号：
US16320238
公开号：
US20190269666A1
申请日:
2017.07.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to a combination therapy with N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (merestinib, LY2801653), or a pharmaceutically acceptable salt thereof, and antibodies that bind human co-inhibitory immune checkpoints such as Programmed Death 1 Ligand 1 (PD-L1) or Programmed Death 1 (PD-1) for the treatment of various cancers.
